The table below shows Tango Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$62.38M
$42.07M
$36.53M
$24.86M
$37.04M
$7.66M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$132.16M
$143.92M
$115.20M
$105.91M
$77.64M
$49.99M
SG&A
$41.51M
TNGX annual revenue (10-K history)
Tango Therapeutics, Inc. reported annual revenue of $62.38M for fiscal year 2025. That is up 48.3% from $42.07M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $7.66M (FY 2020) to $62.38M. Figures come from the company's audited annual reports as filed with the SEC.